|
|
|
Volumn 9, Issue 4, 2006, Pages 256-260
|
|
Drug discovery technology Europe 2006 - IBC's Tenth Annual Conference and exhibition. 13-16 March 2006, London, UK
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID;
ABT 874;
ADIPONECTIN;
ALX 0071;
ANGIOPOIETIN 2;
ANTIRHEUMATIC AGENT;
BAY 632521;
BAY 684986;
BEVACIZUMAB;
CANTUZUMAB MERTANSINE;
CARDIOVASCULAR AGENT;
CYTOKINE ANTIBODY;
HUMAX-CD20;
INTERLEUKIN 2 ANTIBODY;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY C242 DM4;
MONOCLONAL ANTIBODY CD20;
PARACETAMOL;
POLYCLONAL ANTIBODY;
RITUXIMAB;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ACUTE HEART FAILURE;
ANTIANGIOGENIC ACTIVITY;
ATHEROSCLEROSIS;
BREAST CANCER;
CARDIOVASCULAR DISEASE;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL;
COMPUTER PROGRAM;
COMPUTER SYSTEM;
CONFERENCE PAPER;
CORONARY ARTERY DISEASE;
DIABETES MELLITUS;
DOSE RESPONSE;
DRUG BIOAVAILABILITY;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TARGETING;
HIGH THROUGHPUT SCREENING;
HUMAN;
IC 50;
LIVER TOXICITY;
MULTIPLE SCLEROSIS;
NANOTECHNOLOGY;
NONHUMAN;
PHARMACEUTICAL ENGINEERING;
PREDICTION;
PROCESS OPTIMIZATION;
PULMONARY HYPERTENSION;
RIBOSOME;
RISK ASSESSMENT;
UNSPECIFIED SIDE EFFECT;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD20;
CARDIOVASCULAR DISEASES;
DRUG DESIGN;
FEMALE;
HUMANS;
INTERLEUKIN-2;
NEOPLASMS;
TECHNOLOGY, PHARMACEUTICAL;
|
|
EID: 33646019835
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (3)
|
|
References (0)
|
